Compare Amgen, Inc. (AMGN) vs General Mills, Inc. (GIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs General Mills, Inc. — how do they compare? Amgen, Inc. trades at $415.55 (market cap $224.14B), while General Mills, Inc. trades at $38.18 (market cap $20.24B). The key difference: Amgen, Inc. is far larger — about 11.1× General Mills, Inc.'s market cap, and General Mills, Inc. pays the higher dividend (6.43%). Which is the better fit depends on your goals.
| AMGN | GIS | |
|---|---|---|
Market Cap | $224.14B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $417.20 | $51.11 |
52-Week Low | $271.18 | $32.17 |
Enterprise Value | $267.45B | $33.73B |
Dividend Yield | 2.43% | 6.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
General Mills (GIS) trades at $37.97, up 1.89% today, showing a mixed technical picture with a bullish moving average signal but a neutral RSI. Fundamentally, the company reported a net loss in 2026, compressing margins, though it beat Q2 2026 EPS estimates. Recent news highlights strategic partnerships in regenerative agriculture and new product launches to drive growth amid challenging consumer demand.
The outlook is cautious; while the stock appears undervalued on a P/E basis and offers a dividend, significant risks include persistent margin pressure, high debt levels, and weak sales growth. Analyst consensus is predominantly Hold, reflecting uncertainty about the company's turnaround efforts in a competitive market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →
